STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £108.83m
- £120.98m
- $32.18m
REG - Shield Therapeutics - Amends Senior Secured Debt Financing
AnnouncementREG - Shield Therapeutics - Initiation of a Phase II Clinical Trial in Japan
AnnouncementREG - Shield Therapeutics - ACCRUFeR Pediatric PK Results to be Presented
AnnouncementREG - Shield Therapeutics - ACCRUFeR receives Authorisation by Korean Ministry
AnnouncementREG - Shield Therapeutics - Q3 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Grant of Share Options to Chief Executive Officer
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - Positive efficacy and tolerance in pediatric trial
AnnouncementREG - AIM - AIM Notice - 19/09/2025
AnnouncementREG - Shield Therapeutics - £1.5 million placing supporting growth of ACCRUFeR
AnnouncementREG - Shield Therapeutics - ACCRUFeR® assigned Priority Review in US by FDA
AnnouncementREG - Shield Therapeutics - Data published -European Journal of Heart Failure
AnnouncementREG - Shield Therapeutics - Interim results for the six months ended 30 Jun 25
AnnouncementREG - Shield Therapeutics - Q2 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Result of AGM
AnnouncementREG - Shield Therapeutics - Audited results for the year ended 31 Dec 2024
AnnouncementREG - Shield Therapeutics - Licence Agreement in Japan for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Q1 2025 Trading Update
AnnouncementREG - Shield Therapeutics - ACCRUFeR® launched in Canada
Announcement